Oncología preclínica

When your research has the potential to save lives, you deserve a partner with the oncology pharmacology knowledge, breadth of tools and experience to move life-changing drug candidates through non-GLP, preclinical development and oncology clinical trials quickly and efficiently.  

We've helped hundreds of companies discover their next life-improving compound. 

Browse hundreds of cell line growth curves in our complete cell line list or read our spotlights on tumor models. 

We offer over 30 different syngeneic tumor models, from both solid and disseminated origins, to provide you with many choices to further your immuno-oncology research. We are continually improving and expanding adoptive cell therapy capabilities:

• Inmuno-oncología
• Terapias celulares adoptivas 

For over a decade, we have offered an industry-leading array of in vivo imaging modalities for optimum pharmacologic interrogation when needed. Estas incluyen:

• Citometría de flujo 
• Imaging 
• Radiación

LL/2: An Immunosuppressive Murine Tumor Model

El cáncer de pulmón es el segundo cáncer de diagnóstico más frecuente tanto en hombres como en mujeres en los Estados Unidos y es, por amplio margen, la causa más común de muertes relacionadas con cáncer en hombres y mujeres. In 2019, the American Cancer Society estimates that 228.150 new cases of lung cancer (116.440 in men and 111.710 in women) will . . . Read more about the LL/2 model

B16-F10: Un modelo murino de melanoma

Los cánceres de piel incluyen carcinomas de todas las capas de la piel, siendo los más frecuentes los de células basales (BCC) y los de células escamosas (SCC). Melanoma and non-melanoma skin cancers (Merkel cell carcinoma, Kaposi sarcoma, cutaneous lymphoma and other sarcomas) are much less common. . . . Read more about a murine melanoma model

Preclinical Models of Multiple Myeloma

Multiple myeloma is a clonal B cell malignancy characterized by the accumulation of terminally differentiated, antibody-producing plasma cells in the bone marrow that is invasive and drug resistant. Patients are generally asymptomatic until very late state disease. There are few preclinical models that recapitulate human disease. In this work, we have evaluated the human MM.1S model and the murine 5TGM1 model . . . Read more about the preclinical models of multiple myeloma

In-Depth Myeloid Cell Characterization in the Murine Syngeneic CT.26 Colon Carcinoma Model by 10-Color Flow Cytometry

The efficacy of immune-modulating anti-cancer therapeutic antibodies that have been FDA-approved in recent years, such as anti-CTLA-4 and anti-PD-1, has driven growing interest in methods that provide a mechanistic understanding of drug function. . . Read more about In-Depth Myeloid Cell Characterization

• AACR | 24-29 April | San Diego, CA
• Nonclinical Drug Symposium | 6-7 May, Germany